Banque Pictet & Cie Sa Arvinas, Inc. Transaction History

Banque Pictet & Cie Sa

$14.9 Billion
Q4 2024

A detailed history of Banque Pictet & Cie Sa transactions in Arvinas, Inc. stock. As of the latest transaction made, Banque Pictet & Cie Sa holds 110,619 shares of ARVN stock, worth $1.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

110,619

Previous 120,824 8.45%

Holding current value

$1.94 Million

Previous $2.98 Million 28.74%

% of portfolio

0.01%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$17.83 - $28.04 $181,955 - $286,148	-10,205 Reduced 8.45%	110,619 $2.12 Million
Q3 2024 Oct 21, 2024	BUY	$23.66 - $32.73 $909,845 - $1.26 Million	38,455 Added 46.69%	120,824 $2.98 Million
Q2 2024 Jul 25, 2024	SELL	$24.46 - $40.4 $62,397 - $103,060	-2,551 Reduced 3.0%	82,369 $2.19 Million
Q1 2024 May 06, 2024	SELL	$36.38 - $52.31 $291,512 - $419,160	-8,013 Reduced 8.62%	84,920 $3.51 Million
Q4 2023 Feb 09, 2024	BUY	$14.19 - $42.33 $1.32 Million - $3.93 Million	92,933 New	92,933 $3.83 Million
Q1 2023 May 01, 2023	SELL	$26.15 - $37.26 $162,417 - $231,421	-6,211 Reduced 31.2%	13,697 $374,000
Q4 2022 Feb 06, 2023	SELL	$32.47 - $57.24 $203,944 - $359,524	-6,281 Reduced 23.98%	19,908 $0
Q3 2022 Nov 10, 2022	SELL	$41.87 - $57.99 $4,103 - $5,683	-98 Reduced 0.37%	26,189 $1.17 Billion
Q2 2022 Aug 08, 2022	SELL	$36.01 - $74.24 $91,141 - $187,901	-2,531 Reduced 8.78%	26,287 $1.11 Million
Q1 2022 May 04, 2022	BUY	$60.27 - $81.57 $67,201 - $90,950	1,115 Added 4.02%	28,818 $1.94 Million
Q4 2021 Feb 02, 2022	BUY	$65.85 - $96.21 $1.82 Million - $2.67 Million	27,703 New	27,703 $2.28 Million

Others Institutions Holding ARVN

# of Institutions

224

Shares Held

70.9M

Call Options Held

1.52M

Put Options Held

346K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $934M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

News

Stay updated on Banque Pictet & Cie Sa with notifications on news.

Account

Banque Pictet & Cie Sa Arvinas, Inc. Transaction History